Bromodomain-Containing Protein 4: A Druggable Target.

Area of Science:

• Epigenetics and Molecular Biology
• Pharmacology and Drug Discovery

Background:

• Bromodomain-containing protein 4 (BRD4) is an epigenetic regulator involved in transcriptional control via the histone code.
• Initially recognized for its anti-cancer potential, BRD4's role extends to cardiovascular, neurological, and metabolic diseases.
• The development of novel BRD4 inhibitors is crucial given their broad therapeutic implications.

Purpose of the Study:

• To review natural product-derived and synthetic inhibitors targeting Bromodomain-containing protein 4 (BRD4).
• To summarize the therapeutic applications of BRD4 inhibitors across diverse disease areas.
• To highlight the ongoing clinical relevance and future potential of BRD4 inhibition.

Main Methods:

• Literature review of studies on Bromodomain-containing protein 4 (BRD4) inhibitors.
• Analysis of natural product sources and synthetic compounds targeting BRD4.
• Examination of BRD4 inhibitor applications in various pathological conditions.

Main Results:

• Identified diverse natural and synthetic compounds as BRD4 inhibitors.
• Demonstrated the efficacy of BRD4 inhibitors in preclinical and clinical studies for cancer.
• Highlighted emerging applications in metabolic disorders, inflammation, neurological conditions, HIV, and renal fibrosis.

Conclusions:

• Bromodomain-containing protein 4 (BRD4) inhibitors represent a versatile therapeutic strategy.
• Further research into novel BRD4 inhibitors is warranted for treating a spectrum of diseases.
• BRD4 inhibition holds significant promise for future drug development.